― Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ― ― Successful completion of debt refinancing, enhancing financial flexibility through improved terms and reduced amortization obligations ― ― Full-year 2025 revenue and adjusted EBITDA guidance ranges narrowed; adjusted diluted EPS updated to reflect debt refinancing ― Third Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $700 million, as reported Non-respiratory revenue was $588 million, an increase of 5% as reported and 4% in constant currency; excluding Donor Screening1, non-respiratory revenue grew 6% in constant currency Labs revenue grew 5% as reported and 4% in constant currency Respiratory revenue was $112 million as reported; the decline was primarily driven by a 63% decrease in COVID-19 revenue GAAP operating expenses2 decreased by 6%; non-GAAP operating expenses decreased by 7%, both driven by the Company's cost-savings initiatives GAAP net loss margin was (105%); GAAP operating margin was (101%), which included a $701 million non-cash goodwill impairment charge (see description below); adjusted EBITDA margin was 25%, a 180 basis point improvement compared to the prior year period GAAP diluted loss per share was $10.78; adjusted diluted earnings per share ("EPS") was $0.80 SAN DIEGO , Nov. 5, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the third quarter ended September 28, 2025. "Our third quarter results reflect continued execution and meaningful progress against our strategic and financial priorities," said Brian J.
